Search hospitals > Indiana > Indianapolis

Veterans Affairs Medical Center - Indianapolis (Roudebush)

Claim this profile
Indianapolis, Indiana 46202
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Prostate Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Stroke
184 reported clinical trials
9 medical researchers
Photo of Veterans Affairs Medical Center - Indianapolis (Roudebush) in IndianapolisPhoto of Veterans Affairs Medical Center - Indianapolis (Roudebush) in IndianapolisPhoto of Veterans Affairs Medical Center - Indianapolis (Roudebush) in Indianapolis

Summary

Veterans Affairs Medical Center - Indianapolis (Roudebush) is a medical facility located in Indianapolis, Indiana. This center is recognized for care of Cancer, Lung Cancer, Prostate Cancer, Non-Small Cell Lung Cancer, Stroke and other specialties. Veterans Affairs Medical Center - Indianapolis (Roudebush) is involved with conducting 184 clinical trials across 232 conditions. There are 9 research doctors associated with this hospital, such as Kathy Miller, MD, Shadia Jalal, MD, Marianne Sassi Matthias, PhD MS BA, and Trent J. Miller.

Area of expertise

1Cancer
Global Leader
Veterans Affairs Medical Center - Indianapolis (Roudebush) has run 23 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage I
2Lung Cancer
Global Leader
Veterans Affairs Medical Center - Indianapolis (Roudebush) has run 23 trials for Lung Cancer. Some of their research focus areas include:
Stage I
Stage II
Stage III

Top PIs

Clinical Trials running at Veterans Affairs Medical Center - Indianapolis (Roudebush)

Lung Cancer
Non-Small Cell Lung Cancer
Prostate Cancer
Cancer
ALK Gene Rearrangement
Lung Adenocarcinoma
High Blood Pressure
Lung Carcinoma
Kidney Failure
Oligometastasis
Image of trial facility.

Crizotinib

for Non-Small Cell Lung Cancer

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Image of trial facility.

Sotorasib

for Non-Small Cell Lung Cancer

This phase II Lung-MAP treatment trial studies the effect of AMG 510 in treating non-squamous non-small cell lung cancer that is stage IV or has come back (recurrent) and has a specific mutation in the KRAS gene, known as KRAS G12C. Mutations in this gene may cause the cancer to grow. AMG 510, a targeted treatment against the KRAS G12C mutation, may help stop the growth of tumor cells.
Recruiting2 awards Phase 219 criteria
Image of trial facility.

Surgery vs Stereotactic Radiotherapy

for Lung Cancer

Patients with stage I non-small cell lung cancer have been historically treated with surgery whenever they are fit for an operation. However, an alternative treatment known as stereotactic radiotherapy now appears to offer an equally effective alternative. Doctors believe both are good treatments and are therefore conducting this study to determine if one may be possibly better than the other.
Recruiting1 award N/A16 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Veterans Affairs Medical Center - Indianapolis (Roudebush)?
Veterans Affairs Medical Center - Indianapolis (Roudebush) is a medical facility located in Indianapolis, Indiana. This center is recognized for care of Cancer, Lung Cancer, Prostate Cancer, Non-Small Cell Lung Cancer, Stroke and other specialties. Veterans Affairs Medical Center - Indianapolis (Roudebush) is involved with conducting 184 clinical trials across 232 conditions. There are 9 research doctors associated with this hospital, such as Kathy Miller, MD, Shadia Jalal, MD, Marianne Sassi Matthias, PhD MS BA, and Trent J. Miller.